1462-0324 < 1462-0332 < 1462-2416

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by 1462-0332

Number of relevant bibliographic references: 200.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000038 (2020)	Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne]	Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
000056 (2020)	Martin Krusche [Allemagne] ; Nikolas Ruffer [Allemagne] ; Udo Schneider [Allemagne] ; Marco Meyer [Allemagne] ; Gerd Burmester [Allemagne] ; Ina Kötter [Allemagne]	Tocilizumab treatment for polyarteritis nodosa.
000298 (2020)	Yoshikazu Nakaoka ; Mitsuaki Isobe ; Yoshiya Tanaka ; Tomonori Ishii ; Seido Ooka ; Hiroaki Niiro [Japon] ; Naoto Tamura ; Shogo Banno ; Hajime Yoshifuji [Japon] ; Yasushi Sakata ; Atsushi Kawakami ; Tatsuya Atsumi ; Shunsuke Furuta ; Hitoshi Kohsaka ; Katsuya Suzuki ; Ryoki Hara ; Yasuhiro Maejima ; Hiroshi Tsukamoto ; Yoshinari Takasaki ; Katsuhisa Yamashita ; Norihiro Okada ; Shinji Yamakido ; Syuji Takei ; Shumpei Yokota [Japon] ; Norihiro Nishimoto [Japon]	Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
000408 (2020)	Minna-Maija Grönlund [Finlande] ; Terhi Remes-Pakarinen ; Liisa Kröger ; Kati Markula-Patjas ; Maria Backström ; Anne Putto-Laurila [Finlande] ; Kristiina Aalto ; Paula V H Salo	Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
000494 (2020)	Naoto Sakumura [Japon] ; Hitoshi Irabu [Japon] ; Natsumi Inoue [Japon] ; Mao Mizuta [Japon] ; Masaki Shimizu [Japon]	Clinical usefulness of longitudinal IL-6 monitoring in a patient with Takayasu aortitis receiving tocilizumab.
000562 (2020)	Hiroki Yamada [Japon] ; Yuko Kaneko [Japon] ; Hiroya Tamai [Japon] ; Tsutomu Takeuchi [Japon]	Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab.
000653 (2019)	Lianne Kearsley-Fleet [Royaume-Uni] ; Sunil Sampath [Royaume-Uni] ; Liza J. Mccann [Royaume-Uni] ; Eileen Baildam [Royaume-Uni] ; Michael W. Beresford [Royaume-Uni] ; Rebecca Davies [Royaume-Uni] ; Diederik De Cock [Royaume-Uni] ; Helen E. Foster [Royaume-Uni] ; Taunton R. Southwood [Royaume-Uni] ; Wendy Thomson [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]	Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom.
000705 (2019)	Shuntaro Saito ; Ayumi Okuyama ; Yusuke Okada ; Akiko Shibata ; Ryota Sakai ; Takahiko Kurasawa ; Tsuneo Kondo ; Hirofumi Takei ; Koichi Amano	Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study.
000721 (2019)	Jumpei Saito ; Naho Yakuwa ; Kayoko Kaneko [Japon] ; Chinatsu Takai ; Mikako Goto ; Ken Nakajima ; Akimasa Yamatani ; Atsuko Murashima	Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum.
000755 (2019)	Shirly Frizinsky [Israël] ; Soad Haj-Yahia [Israël] ; Diti Machnes Maayan [Israël] ; Yulia Lifshitz [Israël] ; Ramit Maoz-Segal [Israël] ; Irean Offengenden [Israël] ; Mona Kidon [Israël] ; Nancy Agmon-Levin [Israël]	The innate immune perspective of autoimmune and autoinflammatory conditions
000867 (2019)	Paul Emery [Royaume-Uni] ; Juan Rondon [États-Unis] ; Janie Parrino [États-Unis] ; Yong Lin [États-Unis] ; Claudia Pena-Rossi [États-Unis] ; Hubert Van Hoogstraten [États-Unis] ; Neil M H. Graham [États-Unis] ; Nancy Liu [États-Unis] ; Anne Paccaly [États-Unis] ; Richard Wu [États-Unis] ; Alberto Spindler [Argentine]	Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
000882 (2019)	Sabine Adler [Allemagne] ; Stephan Reichenbach ; Andrea Gloor ; Daniel Yerly [Suisse] ; Jennifer L. Cullmann [Suisse] ; Peter M. Villiger	Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis.
000902 (2019)	Shunsuke Mori [Japon] ; Tamami Yoshitama [Japon] ; Yasuyo Abe [Japon] ; Toshihiko Hidaka [Japon] ; Naoyuki Hirakata [Japon] ; Kiyoshi Aoyagi [Japon] ; Yukitaka Ueki [Japon]	Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
000954 (2019)	Diederik De Cock [Belgique] ; Patrick Verschueren [Belgique]	Primus inter pares: the choice of biologic drugs in rheumatoid arthritis.
000979 (2019)	Yoshifumi Tada [Japon] ; Mariko Sakai [Japon] ; Yoshinobu Nakao [Japon] ; Akihito Maruyama [Japon] ; Nobuyuki Ono [Japon] ; Syuichi Koarada [Japon]	Placental transfer of tocilizumab in a patient with rheumatoid arthritis.
000A16 (2019)	Kathrine L. Gr N [Danemark] ; Bente Glintborg [Danemark] ; Mette N Rgaard ; Frank Mehnert ; Mikkel Stergaard [Danemark] ; Lene Dreyer ; Niels S. Krogh [Danemark] ; Merete L. Hetland [Danemark]	Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
000A30 (2019)	Martin Sch Fer [Allemagne] ; Yvette Mei Ner [Allemagne] ; Jörn Kekow ; Sylvia Berger ; Sven Remstedt [Allemagne] ; Bernhard Manger [Allemagne] ; Joachim Listing [Allemagne] ; Anja Strangfeld [Allemagne] ; Angela Zink [Allemagne]	Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.
000A80 (2019)	Sophia C. Weinmann [États-Unis] ; David S. Pisetsky [États-Unis]	Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
000A86 (2019)	Neil M. Steven [Royaume-Uni] ; Benjamin A. Fisher [Royaume-Uni]	Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
000A87 (2019)	Jan Leipe [Allemagne] ; Xavier Mariette [France]	Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
000B09 (2019)	Ariane Klein [Allemagne] ; Jens Klotsche [Allemagne] ; Boris Hügle [Allemagne] ; Kirsten Minden [Allemagne] ; Anton Hospach [Allemagne] ; Frank Weller-Heinemann [Allemagne] ; Tobias Schwarz [Allemagne] ; Frank Dressler [Allemagne] ; Ralf Trauzeddel [Allemagne] ; Markus Hufnagel [Allemagne] ; Ivan Foeldvari [Allemagne] ; Michael Borte [Allemagne] ; Jasmin Kuemmerle-Deschner [Allemagne] ; Jürgen Brunner [Autriche] ; Prasad Thomas Oommen [Allemagne] ; Dirk Föll [Allemagne] ; Klaus Tenbrock [Allemagne] ; Andreas Urban [Allemagne] ; Gerd Horneff [Allemagne]	Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i -k "1462-0332" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/ISSN.i  \
                -Sk "1462-0332" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1462-0332
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021